Current through September 17, 2024
Prior to prescribing, dispensing, or administering cross-sex
hormones for the treatment of gender nonconformity or gender dysphoria,
prescribing practitioners must meet the following:
(A) Obtain three hours of Category 1
Continuing Competency Education for prescribing drugs for the purpose of
treating gender nonconformity or gender dysphoria within the most recent
biennial renewal period;
(B)
Determine or document:
(i) Puberty blocking
treatment, if occurring, has been successful at reducing patient distress and
discomfort;
(ii) That gender
nonconformity or gender dysphoria is driving the patient's distress and not
other mental or physical health conditions, that there is no reasonable
expectation of natural resolution of gender nonconformity, and that there has
been a long-lasting and intense pattern of gender nonconformity or gender
dysphoria which began or worsened at the start of puberty;
(iii) There is an expectation of increased
distress if puberty blocking treatment is terminated or cross-sex hormone
treatment is not initiated;
(iv)
Cross-sex hormones would be effective and are not likely to negatively impact,
or exacerbate other mental or physical health conditions;
(v) The patient has received at least 40
contact hours of therapeutic treatment as required by this chapter;
(vi) The patient has at least six consecutive
months of living primarily as the preferred gender and has continued living
primarily as the preferred gender;
(vii) For individuals not suffering from
gender dysphoria or for whom a clinical diagnosis of gender dysphoria is not
available, documentation that without cross-sex hormone treatment the patient
will experience harm; and
(viii) The
appropriate supports are in place for the patient including appropriate social,
and familial support prior to initiating cross-sex hormone treatment;
(C) Discuss the following with the
patient and parent or legal guardian or the patient, if the patient is an
emancipated minor:
(i) The recommended dosage
and route of treatment for the cross-sex hormones: and
(ii) The minimum waiting period of seven
calendar days as required by this chapter;
(D) Obtain signed informed consent and
patient assent as required by this chapter: and
(E) Document all the foregoing in the
patient's medical record.
